Following the acquisition of Katalyst Surgical, Inc. in 2022, FCI is excited to announce the expansion of its anterior segment portfolio with advanced instruments. Our newly expanded portfolio includes a wide range ultrasharp Gemcision™ sapphire blades.

Following the acquisition of Katalyst Surgical, Inc. in 2022, FCI is excited to announce the expansion of its vitreoretinal portfolio with advanced surgical retina products. Our newly expanded portfolio includes a wide range of vitreoretinal instrumentation, laser probes, illuminated laser probes, chandeliers, backflushes, and cannulas to provide added value to vitreoretinal surgeons.

FCI S.A.S. is a world leader in the development of a wide range of ophthalmic surgical devices. Since the company’s inception in 1984, the innovative developments of FCI have helped physicians to solve problems related to epiphora, dry eye, eyelids, and orbital surgery as well as retinal detachment : highly purified silicone oil and perfluorocarbons, scleral buckling implants, and a wide range of other ophthalmic surgical devices such as disposable vitrectomy lenses, single use instruments and directional laser probes.

FCI S.A.S. is a world leader in the development of a wide range of ophthalmic surgical devices. Since the company’s inception in 1984, the innovative developments of FCI have helped physicians to solve problems related to epiphora, dry eye, eyelids, and orbital surgery, thanks to a wide range of innovative ophthalmic devices such as self-retaining intubation sets, lacrimal balloon catheter, injectable monocanalicular intubation, permanent punctal plugs, eyelids and orbital implants.

FCI S.A.S. is a world leader in the development of a wide range of ophthalmic surgical devices. Since the company’s inception in 1984, the innovative developments of FCI have helped physicians to solve problems related to epiphora, dry eye, eyelids, and orbital surgery, thanks to a wide range of innovative ophthalmic devices and reusable instruments.